ArticleDrugs in context2023

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors.

Darren Mc Poon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.